Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML

Overview

Journal Blood Cancer Discov

Specialties Hematology
Oncology

Date 2023 Nov 2

PMID 37917833

Authors

Brunangelo Falini

Richard Dillon

Affiliations

Soon will be listed here.

Abstract

Significance: NPM1-mutated AML represents a distinct entity in the 2022 International Consensus Classification and 5th edition of World Health Organization classifications of myeloid neoplasms. The correct diagnosis of NPM1-mutated AML and its distinction from other AML entities is extremely important because it has clinical implications for the management of AML patients, such as genetic-based risk stratification according to 2022 ELN. Monitoring of MRD by qRT-PCR, combined with ELN risk stratification, can guide therapeutic decisions at the post-remission stage, e.g., whether or not to perform allogeneic hematopoietic stem cell transplantation.

Citing Articles

Acute myeloid leukemia management and research in 2025.

Kantarjian H, DiNardo C, Kadia T, Daver N, Altman J, Stein E CA Cancer J Clin. 2024; 75(1):46-67.

PMID: 39656142 PMC: 11745214. DOI: 10.3322/caac.21873.

METTL3/YTDHF1 Stabilizes CSRP1 mRNA to Regulate Glycolysis and Promote Acute Myeloid Leukemia Progression.

Han L, Wang R, He M, Chen Z, Wang F Cell Biochem Biophys. 2024; .

PMID: 39565517 DOI: 10.1007/s12013-024-01610-4.

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.

Zheng S, Tong Y, Yang L, Chen J, Tan Y Ann Hematol. 2024; 103(12):5019-5033.

PMID: 39467855 DOI: 10.1007/s00277-024-06050-x.

Mutant NPM1 marginally impacts ribosome footprint in acute myeloid leukemia cells.

Brunetti L, Pianigiani G, Gundry M, Goodell M, Falini B EJHaem. 2024; 5(5):1028-1032.

PMID: 39415917 PMC: 11481009. DOI: 10.1002/jha2.996.

Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?.

Castano-Diez S, Alamo J, Lopez-Guerra M, Gomez-Hernando M, Zugasti I, Jimenez-Vicente C Oncologist. 2024; 30(2).

PMID: 39349391 PMC: 11884738. DOI: 10.1093/oncolo/oyae246.

References

Papaemmanuil E, Dohner H, Campbell P . Genomic Classification in Acute Myeloid Leukemia. N Engl J Med. 2016; 375(9):900-1. DOI: 10.1056/NEJMc1608739. View

Issa G, Ravandi F, DiNardo C, Jabbour E, Kantarjian H, Andreeff M . Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021; 35(9):2482-2495. DOI: 10.1038/s41375-021-01309-y. View

DiNardo C, Tiong I, Quaglieri A, MacRaild S, Loghavi S, Brown F . Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020; 135(11):791-803. PMC: 7068032. DOI: 10.1182/blood.2019003988. View

Wertheim G, Bagg A . Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling mutations and duality of molecular genetic testing methodologies. J Mol Diagn. 2008; 10(3):198-202. PMC: 2329783. DOI: 10.2353/jmoldx.2008.080019. View

Lesieur A, Thomas X, Nibourel O, Boissel N, Fenwarth L, de Botton S . Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. Haematologica. 2020; 106(6):1767-1769. PMC: 8168487. DOI: 10.3324/haematol.2020.260133. View

Brunetti L, Gundry M, Sorcini D, Guzman A, Huang Y, Ramabadran R . Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell. 2018; 34(3):499-512.e9. PMC: 6159911. DOI: 10.1016/j.ccell.2018.08.005. View

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

Eckardt J, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S . Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification. Leukemia. 2023; 37(11):2282-2285. PMC: 10624615. DOI: 10.1038/s41375-023-02016-6. View

Kayser S, Dohner K, Krauter J, Kohne C, Horst H, Held G . The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2010; 117(7):2137-45. DOI: 10.1182/blood-2010-08-301713. View

10.

Falini B, Martelli M, Brunetti L, Gjertsen B, Andresen V . The NPM1 mutant defines AML irrespective of blast count. Am J Hematol. 2023; 98(7):E187-E189. DOI: 10.1002/ajh.26946. View

11.

Ottone T, Ammatuna E, Lavorgna S, Noguera N, Buccisano F, Venditti A . An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn. 2008; 10(3):212-6. PMC: 2329785. DOI: 10.2353/jmoldx.2008.070166. View

12.

Lindsley R, Mar B, Mazzola E, Grauman P, Shareef S, Allen S . Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125(9):1367-76. PMC: 4342352. DOI: 10.1182/blood-2014-11-610543. View

13.

Tiong I, Dillon R, Ivey A, Teh T, Nguyen P, Cummings N . Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol. 2020; 192(6):1026-1030. PMC: 8048658. DOI: 10.1111/bjh.16722. View

14.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars F, Al Hinai A, Zeilemaker A . Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med. 2018; 378(13):1189-1199. DOI: 10.1056/NEJMoa1716863. View

15.

Borate U, Yang F, Press R, Ruppert A, Jones D, Caruthers S . Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories. Blood Adv. 2023; 7(20):6048-6054. PMC: 10582272. DOI: 10.1182/bloodadvances.2022009008. View

16.

Luskin M, Huen A, Brooks S, Stewart C, Watt C, Morrissette J . NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features. Haematologica. 2015; 100(10):e412-4. PMC: 4591778. DOI: 10.3324/haematol.2015.129346. View

17.

Wang P, Segal J, Drazer M, Venkataraman G, Arber D, Gurbuxani S . exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring. EJHaem. 2022; 3(3):962-965. PMC: 9421992. DOI: 10.1002/jha2.445. View

18.

Heuser M, Freeman S, Ossenkoppele G, Buccisano F, Hourigan C, Ngai L . 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767. PMC: 8718623. DOI: 10.1182/blood.2021013626. View

19.

Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W . Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 2010; 115(18):3776-86. DOI: 10.1182/blood-2009-08-240457. View

20.

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View